Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 385.01Cr 337Cr 311.09Cr 290.18Cr 546.75Cr 36TCr 556.53Cr 3.73TCr 1.45TCr 18TCr 1.45TCr 1.41TCr 63TCr P/E 2026 *
16.1x
P/E 2027 * 13.1x
Enterprise Value 385.01Cr 337Cr 311.09Cr 290.18Cr 546.75Cr 36TCr 556.53Cr 3.73TCr 1.45TCr 18TCr 1.45TCr 1.41TCr 63TCr EV / Sales 2026 *
6.05x
EV / Sales 2027 * 5.36x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day-0.05%
1 week+0.14%
Current month+0.69%
1 month+0.56%
3 months+32.23%
6 months+35.02%
Current year+34.73%
1 week 31.39
Extreme 31.39
31.5
1 month 31.25
Extreme 31.25
31.5
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.68
Extreme 0.68
32.56
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Chief Tech/Sci/R&D Officer 62 01/06/2025
Director TitleAgeSince
Chairman 78 01/01/2002
Director/Board Member 62 01/10/2002
Director/Board Member 65 19/02/2015
Date Insider Type Main position Quantity % Market Cap.
03/06Fiscal year

Chief Technology Officer

3,795 0.0031%
17/02Fiscal year

Head of Human Resources

1,585 0.0013%
05/01Fiscal year

Chief Executive Officer

94,787 0.0771%
Change 5-day change 1-year change 3-year change Capi.($)
-0.05%+0.14%+44.91%+133.97% 385.01Cr
-0.81%+1.60%+19.60%-12.61% 6.43TCr
-0.57%+4.09%+56.93%+222.66% 5.73TCr
-3.94%+39.10%+39.10%+39.10% 4.34TCr
-0.56%+1.65%-51.04%-58.77% 3.8TCr
+0.36%+10.24%+73.09%-23.68% 3.2TCr
+0.98%+16.80%+158.25%-41.36% 2.77TCr
-0.41%+9.52%+67.90%+83.68% 2.29TCr
-0.56%+5.64%+2.91%+174.96% 1.77TCr
-0.13%-0.94%+60.31%+119.58% 1.64TCr
Average -0.56%+6.44%+47.20%+63.75% 3.24TCr
Weighted average by Cap. -0.80%+6.08%+42.54%+52.56%

Financials

2026 *2027 *
Net sales 64Cr 56Cr 51Cr 48Cr 90Cr 6.02TCr 92Cr 616.61Cr 239.38Cr 2.97TCr 239.02Cr 233.68Cr 10TCr 72Cr 63Cr 58Cr 54Cr 101.95Cr 6.79TCr 103.77Cr 695.79Cr 270.12Cr 3.35TCr 269.71Cr 263.69Cr 12TCr
Net income 23Cr 20Cr 19Cr 17Cr 33Cr 2.19TCr 33Cr 224.02Cr 87Cr 1.08TCr 87Cr 85Cr 3.76TCr 32Cr 28Cr 26Cr 24Cr 45Cr 2.99TCr 46Cr 306.49Cr 118.99Cr 1.48TCr 118.81Cr 116.15Cr 5.14TCr
Net Debt - -
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Date Price Change Volume
30/26/30 $31.44 -0.06% 40,20,697
29/26/29 $31.46 -0.13% 17,52,851
26/26/26 $31.50 +0.25% 40,67,136
25/26/25 $31.42 0.00% 11,70,475
24/26/24 $31.42 +0.06% 11,80,755
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
31.46USD
Average target price
31.67USD
Spread / Average Target
+0.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CPRX Stock